Tune into the April 10, 2009, edition of WLS News to find out about a new obesity drug that could get FDA approval, learn why high fructose corn syrup may be the cause of our nation’s continued weight gain, and discover what Canadian authorities are doing to curb childhood obesity up north. Plus, we’ll explain why a couple pounds’ difference in infants could lead to future obesity, and how genetic differences may protect some ethnic groups from fatty liver disease. It’s all in this week’s action-packed episode of WLS News!
Vivus obesity drug may get broader label
While Arena's lorcaserin has been connected to possible cancer risks, Orexigen's Contrave was sent back on heart safety concerns. Orexigen's shares were trading up 1 percent, while those of Arena were trading down 1 percent on the Nasdaq.
Read more on Reuters
